Publications

Presentations and Publications

September, 2026

Safety, translational biomarkers and lung function with the oral RARβ/γ-selective agonist GRI-0621 in idiopathic pulmonary fibrosis: a Phase 2a randomised, double-blind, placebo controlled trial (GRI-0621-IPF-02)

H. Parfrey, J.C. Porter, P. Saunders, N. Chaudhuri, N. Hirani, A. Crawshaw, M. Gibbons, A. Menon, S. Schembri, V. Kumar, A. Agro, M. Hertz

September 06, 2026, Barcelona, Spain

GRI-0621 Phase 2a biomarker study in patients with IPF using gene expression, immune cell activity and collagen markers supports a repair phenotype with strong anti-fibrotic and pro-resolving effects

M. Hertz, J.C. Porter, H. Parfrey, P. Saunders, N. Chaudhuri, N. Hirani6 A. Crawshaw, M. Gibbons, A. Menon, S. Schembri, V. Kumar, A. Agro

September 06, 2026, Barcelona, Spain

GRI-0621 Phase 2a biomarker study in patients with IPF: GRI-0621 has a positive effect on FVC after 12 weeks of treatment

J.C. Porter, H. Parfrey, P. Saunders, N. Chaudhuri, N. Hirani, A. Crawshaw, M. Gibbons, A. Menon, S. Schembri, V. Kumar, M. Hertz, A. Agro

September 06, 2026, Barcelona, Spain

GRI-0621 phase 2a biomarker study in patients with IPF: a safety signal demonstrating favorable tolerability

H. Parfrey, J.C. Porter, P. Saunders, N. Chaudhuri, N. Hirani, A. Crawshaw, M. Gibbons, A. Menon, S. Schembri, V. Kumar, A. Agro, M. Hertz

September 06, 2026, Barcelona, Spain

May, 2025

Inactivation of iNKT Cells After the Inflammatory Phase Leads to Significant Inhibition of Fibroblast Activation and Fibrosis in a Model of Pulmonary Fibrosis

Marc Hertz, A.Agro, V. Kumar
May 21, 2025, San Francisco, CA

November, 2024

A New Approach to Inflammatory Diseases

Marc Hertz PhD, Chief Executive Officer of GRI Bio
November 21, 2024, Boston, MA

November, 2024

8th Annual Antifibrotic Drug Development (AFDD) Summit

Involvement Of Type 1 Invariant Natural Killer T Cells In Driving Lung Fibrosis

October, 2024

22nd International Colloquium on Lung and Airway Fibrosis (ICLAF 2024)

Involvement Of Type 1 Invariant Natural Killer T Cells In Driving Lung Fibrosis

July, 2024

American Journal of Respiratory and Critical Care Medicine

Type 1 Invariant Natural Killer T Cells Drive Lung Fibrosis

May, 2024

14th International Congress on Autoimmunity

2024 ATS International Conference

October, 2023

7th Antifibrotic Drug Development Summit

October, 2023

Altered NKT cell populations in the airways of patients with IPF

September, 2023

Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis

May, 2020

Differential Activation of Unconventional T Cells, Including iNKT Cells, in Alcohol-Related Liver Disease.

February, 2019
American Journal of Physiology

Intestinal iNKT cells migrate to liver and contribute to hepatocyte apoptosis during alcoholic liver disease.

November, 2018

Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis.

September, 2018
Frontiers in Immunology

Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut.

February, 2018
Gastroenterology

Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice.

February, 2017

Type II NKT Cells and Their Emerging Role in Health and Disease.

March, 2016
Cellular and Molecular Immunology

Invariant natural killer T cells contribute to chronic-plus-binge ethanol-mediated liver injury by promoting hepatic neutrophil infiltration.

April, 2015
Heptology

Inhibition of type I natural killer T cells by retinoids or following sulfatide-mediated activation of type II natural killer T cells attenuates alcoholic liver disease in mice. Heptology; April, 2015

November, 2014

Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease.

September, 2013

NKT-cell subsets: promoters and protectors in inflammatory liver disease.

July, 2007
Journal of Clinical Investigation

Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease.

April, 2004
Journal of Experimental Medicine

Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. 

Our Science

Our Pipeline

Our Team